New pill targets rare cancer gene in 30-Patient trial
NCT ID NCT07359820
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests an oral drug called lirafugratinib in 30 adults with advanced solid tumors (excluding bile duct cancer) that have an FGFR2 gene fusion or rearrangement. Participants take the drug regularly and visit the clinic for checkups. The main goal is to see if the drug shrinks tumors and is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lirafugratinib (a targeted oral drug that blocks FGFR2)
What this could lead to
If it works, this could offer a new treatment option for people with certain hard-to-treat cancers that have an FGFR2 gene change.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The drug may cause side effects or not shrink tumors as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FGFR2 GENE FUSION/REARRANGEMENT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Georges François Leclerc
NOT_YET_RECRUITINGDijon, 21079, France
-
Centre Leon Berard
NOT_YET_RECRUITINGLyon, 69373, France
-
Gustave Roussy Cancer Campus
NOT_YET_RECRUITINGParis, 94805, France
-
Hospital Universitario Fundación Jiménez Díaz- START MADRID
NOT_YET_RECRUITINGMadrid, 28040, Spain
-
Hospital Universitario HM Sanchinarro-START MADRID-CIOCC
NOT_YET_RECRUITINGMadrid, 28050, Spain
-
Institut Bergonie
NOT_YET_RECRUITINGBordeaux, 33076, France
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact
Contact Phone: •••-•••-••••
-
Mayo Clinic
NOT_YET_RECRUITINGPhoenix, Arizona, 85054, United States
-
Mayo Clinic
NOT_YET_RECRUITINGJacksonville, Florida, 32224, United States
-
Mayo Clinic
NOT_YET_RECRUITINGRochester, Minnesota, 55905, United States
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact Phone: •••-•••-••••
Contact
-
START Barcelona-Hospital HM Nou Delfos
NOT_YET_RECRUITINGBarcelona, 08023, Spain
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
Contact
Contact Phone: •••-•••-••••
-
Sarah Cannon Research Institute UK
NOT_YET_RECRUITINGLondon, W1G 6AD, United Kingdom
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
Contact
Contact Phone: •••-•••-••••
-
The Christie NHS Foundation
NOT_YET_RECRUITINGManchester, M20 4GJ, United Kingdom
-
The University of Texas M.D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-••••
-
University College Hospital (NIHR UCLH Clinical Research Facility)
NOT_YET_RECRUITINGLondon, NW1 2BU, United Kingdom
-
University of Chicago Medical Center
NOT_YET_RECRUITINGChicago, Illinois, 60637, United States